自免疫性肝素诱导的血小板缺血症
Theodore E Warkentin1,2,3
1Department of Pathology and Molecular Medicine and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.
Journal of clinical medicine
|November 14, 2023
概括
自身免疫性HIT (aHIT) 涉及严重的血小板缺血,原因是病理性抗体,独立于肝素. 像IVIG这样的特殊治疗和仔细的抗凝剂选择对于管理这种未被认可的疾病至关重要.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自免疫肝素诱导性血栓缩症 (aHIT) 是肝素诱导性血栓缩症 (HIT) 的严重亚型.
- aHIT的特点是病态的IgG抗体可以独立于肝素激活血小板.
- 非典型的临床特征包括延迟发病,持续性或肝素冲洗的HIT,以及严重的血栓形成,如DIC.
研究的目的:
- 描述自身免疫性HIT (aHIT) 的独特临床特征.
- 为aHIT.IT概述专门的治疗策略.
- 要突出在临床实践中对aHIT的认可不足.
主要方法:
- 临床病例审查和分析aHIT的特征.
- 对IVIG,血交换和直接血栓激素抑制剂 (DTI) 治疗结果的审查.
- 评估HIT实验室的诊断挑战.
主要成果:
- aHIT呈现出对停止服用肝素无反应的血小板缺血.
- 治疗可能需要高剂量的IVIG或血交换.
- 由于DIC和蛋白C激活等混因素,直接血栓抑制剂 (DTIs) 可能效果较差.
结论:
- 与经典的HIT相比,aHIT需要不同的管理策略.
- 早期识别和专门治疗对于改善患者的治疗结果至关重要.
- 目前的HIT实验室测试往往无法识别HIT抗体,导致识别不足.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
719
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
719
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Disorders of Hemostasis
957
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
957
Extrinsic and Intrinsic Pathways of Hemostasis
8.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.0K
Introduction to Hemostasis
8.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
535
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
535


